Straits Times Index
3,300.69 +8.00 (+0.24%) Nikkei
38,281.68 +7.63 (+0.02%) Hang Seng
17,988.35 +225.32 (+1.27%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,274.66 -2,440.96 (-4.09%) CMC Crypto 200
1,256.89 -82.18 (-6.13%)
ACADIA Pharmaceuticals Inc. (ACAD)
After hours:
| Previous close | 16.71 |
| Open | 16.84 |
| Bid | 16.99 x 100 |
| Ask | 17.05 x 300 |
| Day's range | 16.84 - 17.57 |
| 52-week range | 16.16 - 33.99 |
| Volume | |
| Avg. volume | 1,812,929 |
| Market cap | 2.817B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
SAN DIEGO, April 29, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year.
- Business Wire
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
SAN DIEGO, April 24, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
- Business Wire
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
SAN DIEGO, April 22, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
